Thus, TβRII-SE, a newly identified soluble isoform of the TGF-β type II receptor that binds all three TGF-β isoforms, was shown to reduce liver injury and fibrosis in a carbon tetrachloride-induced liver fibrosis animal model, suggesting its potential as a therapeutic agent in fibrotic liver diseases (Bertolio et al., 2021). Here, TGFB1 is linked to Hepatic fibrosis.